Pacific Biosciences
PACB
223 hedge funds and large institutions have $321M invested in Pacific Biosciences in 2026 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 70 increasing their positions, 77 reducing their positions, and 29 closing their positions.
197% more call options, than puts
Call options by funds: $3.08M | Put options by funds: $1.04M
29% more capital invested
Capital invested by funds: $249M → $321M (+$72.3M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.79% less ownership
Funds ownership: 62.31% → 61.52% (-0.79%)
9% less repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 77
3% less funds holding
Funds holding: 231 → 223 (-8)
17% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10.3M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.54M |
| 3 |
Goldman Sachs
New York
|
+$3.26M |
| 4 |
LP
Longaeva Partners
Chicago,
Illinois
|
+$3.08M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$9.44M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
-$2.8M |
| 3 |
Renaissance Technologies
New York
|
-$2.21M |
| 4 |
Morgan Stanley
New York
|
-$1.98M |
| 5 |
Jane Street
New York
|
-$1.97M |
PACB Hedge Fund Activity: Q2 2026 in Review
223 of the 8,295 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q2 2026, worth a combined $321M — up 29% from $249M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of PACB and 24 opened new positions — a net loss of 5 holders — while 77 trimmed existing stakes and 70 added.
The largest buyer was BlackRock, adding an estimated $10.3M. The largest seller was ARK Investment Management, cutting an estimated $9.44M.
- 223 institutional investors held Pacific Biosciences (PACB) as of Q2 2026, down from 231 in Q1 2026.
- Funds reported $321M of Pacific Biosciences stock for Q2 2026, up 29% quarter-over-quarter.
- 24 funds opened new Pacific Biosciences positions in Q2 2026 and 29 closed out, a net change of -5 holders.
- The largest Pacific Biosciences buyer in Q2 2026 was BlackRock, an estimated $10.3M added.
- The largest Pacific Biosciences seller in Q2 2026 was ARK Investment Management, an estimated $9.44M sold.
Based on aggregated 13F filings for Q2 2026.